We help patients beat cancer with tumor-localized therapy.

Learn More

About Shasqi

Shasqi is a privately held, clinical stage biopharmaceutical company who is focused on bringing the advances of click chemistry to help people fight their cancer. We recognized that there was an unmet need that surgery and drug therapy could not address. Leveraging our revolutionary CAPAC™ platform, our lead asset, SQ3370, is able to increase tumor destruction, while avoiding characteristic dose-limiting toxicities.

Click Activated Protodrugs Against Cancer (CAPAC™)

Our revolutionary CAPAC™ platform directs powerful therapies precisely to tumors. Designed to improve efficacy while decreasing systemic toxicity, Shasqi’s CAPAC Platform is highly modular and is a transformative approach that works independently of tumor characteristics, with the potential to help more patients than biomarker-driven therapies can.

Overview of the CAPAC platform development

  • 2001

    The term click chemistry is coined by Kolb, Finn and Sharpless: a highly selective set of chemical reactions that can occur even in a glass of water.

    Read More
  • 2004

    Prescher, Dube, and Bertozzi report the use of click chemistry to modify cells in living animals.

    Read More
  • 2008

    Blackman, Royzen, and Fox pioneer the tetrazine ligation, an exceptionally powerful and efficient type of click chemistry.

    Read More
  • 2014

    Shasqi’s founder presents the foundational concepts of the Click Activated Protodrugs Against Cancer (CAPAC) Platform and shows the concept works in mice using the tetrazine ligation.

    Read More
  • 2016

    Shasqi shows that a cancer drug improved with the CAPAC Platform can lead to fewer side effects and better efficacy against tumors in mice.

    Read More
  • 2019

    Shasqi Announces Series A Financing.

    Read More
  • 2020

    FDA and Australian Ethics Committee provide permission to proceed with first in human clinical study.

    Read More
  • 2020

    Shasqi presents anti-tumor responses for SQ3370, CAPAC’s lead candidate, in preclinical cancer model. (AACR)

    Read More
  • 2020

    The first patient dosed with Shasqi's SQ3370. First ever use of click chemistry in humans.

    Read More